Business
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug
About this update from Incyte Corporation
[{"type":"text","content":"\nIncyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520680248/en/\nBuilding on the companies' initial collaboration announced in February 2025, the expanded agreement broadens the deployment of Genesis’ AI platform, GEMS (Genesis Exploration of Molecular Space) – which includes the leading foundation models for protein-ligand structure and property prediction – across a wider variety of challenging targets in Incyte’s portfolio. Incyte will also share proprietary experimental data with Genesis to enhance GEMS’ capabilities.\n\n\n“This expanded collaboration reflects the strong results from our initial programs and Incyte’s commitment to applying advanced technologies to enhance our discovery engine and accelerate the development of differentiated small molecule medicines,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of R&D. “By combining our deep expertise in drug discovery and development and our significant experimental data with Genesis' AI capabilities, we aim to more efficiently advance priority programs against high-value targets and ultimately bring important new medicines to patients.\"\n\n\n“Our partnership with Incyte reflects the exciting synergy between our AI platform and Incyte’s deep expertise and capabilities in rapid experimental data generation and marks an important moment in the evolution of AI in this vertical,” said Evan Feinberg, Ph.D., Founder and Chief Executive Officer of Genesis. “High-quality proprietary data is among the most valuable inputs for advancing molecular AI, and our expanded collaboration will enable both companies and patients to benefit from an industrial-scale flywheel of AI-enabled design-make-test cycles.\"\n\n\nTerms of the Agreement\nGenesis will receive total upfront consideration of $120 million, which includes an $80 million upfront cash payment and a $40 million purchase of equ...